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Abstract
Background: Interstitial cystitis (IC) is a debilitating disease characterized by chronic inflammation
of the urinary bladder, yet specific cellular mechanisms of inflammation in IC are largely unknown.
Multiple lines of evidence suggest that β-adrenergic receptor (AR) signaling is increased in the
inflamed urothelium, however the precise effects of these urothelial cell signals have not been
studied. In order to better elucidate the AR signaling mechanisms of inflammation associated with
IC, we have examined the effects of β-AR stimulation in an immortalized human urothelial cell line
(UROtsa). For these studies, UROtsa cells were treated with effective concentrations of the
selective β-AR agonist isoproterenol, in the absence or presence of selective inhibitors of protein
kinase A (PKA). Cell lysates were analyzed by radioimmunoassay for generation of cAMP or by
Western blotting for induction of protein products associated with inflammatory responses.
Results: Radioligand binding demonstrated the presence of β-ARs on human urothelial UROtsa
cell membranes. Stimulating UROtsa cells with isoproterenol led to concentration-dependent
increases of cAMP production that could be inhibited by pretreatment with a blocking
concentration of the selective β-AR antagonist propranolol. In addition, isoproterenol activation of
these same cells led to significant increases in the amount of phosphorylated extracellular signal-
regulated kinase (pERK), inducible nitric oxide synthase (iNOS) and the induced form of
cyclooxygenase (COX-2) when compared to control. Moreover, preincubation of UROtsa cells
with the selective PKA inhibitors H-89 or Rp-cAMPs did not diminish this isoproterenol mediated
phosphorylation of ERK or production of iNOS and COX-2.
Conclusion: Functional β-ARs expressed on human urothelial UROtsa cell membranes increase
the generation of cAMP and production of protein products associated with inflammation when
activated by the selective β-AR agonist isoproterenol. However, the increased production of iNOS
and COX-2 by isoproterenol is not blocked when UROtsa cells are preincubated with inhibitors
of PKA. Therefore, UROtsa cell β-AR activation significantly increases the amount of iNOS and
COX-2 produced by a PKA-independent mechanism. Consequently, this immortalized human
urothelial cell line can be useful in characterizing potential AR signaling mechanisms associated with
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chronic inflammatory diseases of the bladder.
Background
Interstitial cystitis (IC) is a debilitating disease character-
ized by chronic pain in the urinary bladder along with
increased urinary frequency and urgency. IC is a complex
disease with multiple etiologies, yet inflammatory pain is
a common mechanism of all IC symptoms [1]. Prosta-
noids, arachidonic acid metabolites of the cyclooxygenase
(COX) pathway, and nitric oxide (NO), whose formation
is catalyzed by nitric oxide synthase (NOS), both play
major roles in regulating the inflammatory response.
Increased levels of prostaglandins generated by the induc-
ible form of cyclooxygenase (COX-2) mediate the vasodil-
atation and vascular permeability observed during the
early events of inflammation [2]. Moreover, animal mod-
els lacking the PGE2 prostaglandin receptor demonstrate
a reduced algesic response indicating the importance of
prostanoids in the signaling and perception of inflamma-
tory pain [3]. Finally, increased COX-2 expression docu-
mented for an in vivo model of cystitis supports the idea
that increased prostaglandin signaling sensitizes bladder
afferents that control micturition and pain [4].
The expression of the inducible form of NOS, iNOS, has
been characterized in numerous cell types as a conse-
quence of the inflammatory processes that follow tissue
damage [5]. Large amounts of NO generated by iNOS sur-
pass homeostatic concentrations formed by endothelial
eNOS or neuronal nNOS [6]. This difference in kinetics of
NO formation by iNOS leads to multiple inflammatory
responses that include neutrophil activation, DNA dam-
age, protein nitration and induction of apoptosis [5]. Fur-
thermore, animal models deficient in iNOS establish this
enzyme's importance as a pathophysiological mediator of
chronic inflammatory diseases [7]. Moreover, increased
levels of luminal NO, recognized as a causative agent for
bladder excitability and micturition, has been docu-
mented in patients with IC, which could represent a
mechanism of hyperexcitability documented for this dis-
ease [8].
Multiple lines of evidence suggest that increased signaling
through the G protein-coupled β-adrenergic receptor (AR)
may be linked to inflammation associated with IC.
Patients with IC have been found to have increased nerve
fiber innervation of the urinary bladder. Further study has
shown these fibers to be solely sympathetic nerves, which
would correspond to an increase in AR signaling [9].
Moreover, elevated urinary levels of norepinephrine have
been found in IC patients, which is also consistent with
greater AR activity in the urinary bladder [10]. Finally,
genomic profiling found increased transcription of the β2-
AR gene in a mouse bladder inflammation model [11].
Together, these observations suggest that chronic β-AR
stimulation may be linked to inflammatory bladder dis-
eases like IC. Therefore, we hypothesize that urothelial β-
AR activation mediates specific inflammatory responses
that can be linked to bladder hyperexcitability and pain
documented in chronic inflammatory bladder diseases
like IC.
In order to test this hypothesis, we have studied the effects
of β-AR activation in an immortalized cell line of human
urothelium, UROtsa cells [12]. UROtsa cells exhibit
numerous properties of basal bladder epithelial cells,
including the potential to differentiate into the stratified
cell types found in the mammalian bladder lining. Our
results using these UROtsa cells as an in vitro model of
bladder urothelium, reveals a correlation between β-AR
activation and the production of specific pro-inflamma-
tory proteins via a PKA-independent mechanism.
Results
Identification of specific β-AR binding sites
It was important to determine if specific AR binding sites
are expressed on UROtsa cell membranes in order to study
specific inflammatory responses that may be linked to β-
AR activation. Therefore, radioligand binding analysis was
performed to characterize the level of β-AR expression on
UROtsa cell membranes. Increasing amounts of the iodi-
nated non-selective β-AR antagonist (-)3-[125I]iodocyano-
pindolol (125I-CYP) specifically labeled a saturable,
homogeneous, high affinity binding site on these UROtsa
membranes (Figure 1). The number of binding sites was
determined to be 951 ± 43 fmol/mg protein (n = 3), and
the equilibrium dissociation constant of 125I-CYP for
these binding sites was 32.4 ± 1.1 pM (n = 3). This 125I-
CYP equilibrium dissociation constant is similar to the
calculated affinity value of this radiochemical when it was
used by others to identify β-AR binding sites on cell mem-
branes [13].
Isoproterenol Induces cAMP Accumulation
β-AR activation is classically linked to adenylate cyclase
activation. Therefore, to test the functionality of β-ARs
expresssed on UROtsa cells, we analyzed levels of cAMP
generated after incubation with a selective β-AR agonist.
Isoproterenol induced a concentration-dependent
increase of cAMP in UROtsa cells (Figure 2). From this
data a concentration-response curve was generated and
used to calculate a half-maximal isoproterenol concentra-
tion (EC50) for generating cAMP in these cells. The calcu-
lated EC50 of 170 ± 66 nM (n = 4) for generating cAMP inCell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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these cells is similar to results by others when isoprotere-
nol was used to stimulate β-AR production of cAMP [13].
In addition, this UROtsa cell response was abated to basal
levels by preincubation with 1 µM of the selective β-AR
antagonist propranolol (data not shown). These results
together demonstrate that β-ARs are expressed on UROtsa
cells and can be stimulated by selective receptor agonists
to generate cAMP, which is characteristically linked to this
AR type.
Selective Production of Inflammatory Mediators by β-AR 
Stimulation
Increased sympathetic innervation and elevated urinary
catecholamine levels in IC patients implies that chronic
bladder inflammation may be linked to stimulation of β-
ARs. Therefore, we stimulated UROtsa cells with an effec-
tive concentration (100 nM) of isoproterenol and probed
the cell lysates for mediators of inflammatory responses
using Western analysis. Semi-qualitative analysis demon-
strated a significant increase in protein levels for COX-2
and iNOS 2 hr after addition of isoproterenol (Figure 3).
Specifically there was a 1.8 ± 0.3 and 2.1 ± 0.3 fold
increase in COX-2 (n = 8) and iNOS (n = 9) expression,
respectively when compared to basal. Conversely, isopro-
terenol treatment did not raise levels of the inflammatory
cytokines IL-1β, IL-10, and IL-8 (data not shown). In sep-
arate experiments, UROtsa cells were also treated with a
nonspecific agent of inflammation in order to confirm the
inflammatory nature of protein expression observed after
isoproterenol addition. Stimulation of UROtsa cells with
300 nM lipopolysaccharide (LPS) induced the expression
of both COX-2 and iNOS (n = 3; Figure 3). Maximum
expression of COX-2 and iNOS was observed 2 hr after
LPS addition, which is similar to the time course observed
using isoproterenol. These results demonstrate a selective
production of inflammatory mediators by UROtsa cells in
response to β-AR activation.
β-AR Mediated Activation of MAPK Pathway
Increased production of inflammatory mediators is asso-
ciated with induction of the mitogen activated protein
Specific β-AR binding sites expressed on UROtsa cell  membranes Figure 1
Specific β-AR binding sites expressed on UROtsa cell 
membranes. UROtsa cell membranes were incubated with 
increasing amounts of 125I-CYP in the absence and presence 
of 10 µM propranolol to determine total and nonspecific 
binding, respectively. Specific 125I-CYP binding was plotted 
versus the amount of free radioligand concentration and fit-
ted to a rectangular hyperbola using non-linear regression 
analysis. From this curve fit the number of specific 125I-CYP 
binding sites was determined to be 951 ± 43 fmol/mg pro-
tein. In addition, the equilibrium dissociation constant of 125I-
CYP for these binding sites was calculated to be 32.4 ± 1.1 
pM. Values are presented as the mean ± S.E. for n = 3 exper-
iments performed in duplicate.
β-AR activation stimulates cAMP production in UROtsa cells Figure 2
β-AR activation stimulates cAMP production in 
UROtsa cells. UROtsa cells incubated for 30 min with the 
selective β-AR agonist isoproterenol generated increasing 
amounts of cAMP in a concentration-dependent manner. 
From these data the concentration of isoproterenol that gen-
erated a half-maximal response (EC50) was calculated using 
non-linear regression analysis. The EC50 value (ϒ) of isoprot-
erenol to increase cAMP in UROtsa cells was calculated to 
be 170 ± 66 nM and is presented as the mean ± S.E. for n = 4 
experiments performed in duplicate.Cell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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kinase (MAPK) signal transduction pathways [14]. Stimu-
lation of β-ARs, although classically linked to cAMP accu-
mulation, has also has been shown to activate pro-
inflammatory MAPK pathways [15]. To test whether β-AR
stimulation activates intercellular MAPK we assayed iso-
proterenol treated UROtsa cells for levels of pERK using
Western analysis. Cells stimulated with an effective iso-
proterenol concentration (100 nM) showed significant
increases in the amount of pERK 5 min after drug addition
(Figure 4). Semi-qualitative analysis revealed a 2.4 ± 0.4
fold increase in pERK levels (n = 10) when compared to
basal while levels of non-phosphorylated ERK2 remained
constant. As a control, UROtsa cells treated with 300 nM
LPS showed an increase in ERK phosphorylation after 5
min, which is similar to what was observed using isopro-
terenol (n = 3; Figure 4). These results demonstrate that a
MAPK signal transduction pathway is activated by UROtsa
cell β-AR stimulation and that ERK phosphorylation pre-
cedes transcriptional induction of COX-2 or iNOS.
ERK Phosphorylation is Independent of cAMP Mediated 
Activation of PKA
Increased levels of cAMP are canonically associated with
subsequent activation of protein kinase A (PKA). While
our results demonstrated a β-AR mediated rise in cAMP
production, it remained unclear whether phosphoryla-
tion of ERK was dependent upon this cAMP-dependent
activation of PKA. Therefore, we studied the effects of
UROtsa cell β-AR stimulation after treatment with selec-
tive concentrations of the PKA inhibitors H-89 or Rp-
UROtsa cell β-AR activation stimulates production of pro- inflammatory mediators Figure 3
UROtsa cell β-AR activation stimulates production of 
pro-inflammatory mediators. UROtsa cells were incu-
bated with 100 nM isoproterenol or 300 nM lipopolysaccha-
ride (LPS) in serum-free DMEM for the indicated times. Cells 
were lysed in modified RIPA and total cell lysates were proc-
essed as described under "Methods" for immunoblotting with 
anti-COX-2 or anti-iNOS antibody to determine β-AR medi-
ated changes in protein expression. As reported by the anti-
body supplier, COX-2 is identified as a doublet band running 
at 72–74 kD, and iNOS is detected as a band at 130 kD. Peak 
expression of the pro-inflammatory mediators COX-2 and 
iNOS was observed 2 hrs after addition of isoproterenol. 
Semi-quantitative analysis revealed that there was a signifi-
cant 1.8 ± 0.3 and 2.1 ± 0.3 fold increase in COX-2 and 
iNOS expression, respectively when compared to basal. Sim-
ilarly, a 2 hr incubation with LPS led to increased expression 
of COX-2 and iNOS when compared to basal. Values are 
presented as the mean ± S.E. and the autoradiographs are 
representative immunoblots of n = 3–9 independent UROtsa 
cell treatments.
β-AR mediated activation of the MAPK pathway Figure 4
β-AR mediated activation of the MAPK pathway. 
UROtsa cells were incubated with 100 nM isoproterenol or 
300 nM LPS for the indicated times, and cell lysates were 
immunoblotted with anti-pERK to determine the receptor 
mediated phosphorylation state of ERK or anti-ERK2 to 
establish the total amount of ERK2 in the samples. As per 
manufacturer's literature, pERK antibody binds phorphor-
ylated ERK1 and ERK2 in two bands found at 44 and 42 kD, 
respectively. The ERK2 antibody only binds ERK2 at 42 kD. 
Peak levels of pERK were observed 5 min after addition of 
isoproterenol with no significant changes in the total cell 
lysate levels of ERK2. Densitometric analysis demonstrated a 
significant 2.4 ± 0.4 fold increase in pERK levels when com-
pared to basal. Similarly, LPS treatment also increased ERK 
phosphorylation over basal within 5 min without a change in 
ERK2 production. Values are presented as the mean ± S.E. 
and the autoradiographs are representative of n = 3–10 inde-
pendent UROtsa cell treatments.Cell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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cAMPS. Cell pretreatment in serum-free DMEM contain-
ing 100 nM of H-89 or 10 µM of Rp-cAMPS did not signif-
icantly alter levels of pERK after stimulation with
isoproterenol when compared to cells preincubated in the
absence of PKA inhibitors (Figure 5). Increases in pERK
when compared to basal were still detected following H-
89 or Rp-cAMPS pretreatment with peak levels generated
at 5 min. Semi-quantitave analysis of the immunoblots
revealed a 1.9 ± 0.4 and 2.6 ± 0.7 fold increase in pERK
levels over basal after H-89 (n = 4) or Rp-cAMPS (n = 3)
pretreatment, respectively, which are not significantly dif-
ferent than the fold increase for pERK observed without
inhibitor pretreatment (2.6 ± 0.9; n = 4). Results of these
experiments demonstrate that β-AR stimulated MAPK
activation in UROtsa cells is not dependent upon genera-
tion of cAMP production and subsequent activation of
PKA.
PKA-Independent Production of Inflammatory Mediators
Although previous results revealed that MAPK activation
is not dependent upon PKA activation, we were interested
in whether or not production of inflammatory mediators
initiated by β-AR activation also occurred under PKA-
independent mechanisms. Pretreatment of UROtsa cells
with selective concentrations of H-89 (100 nM) or Rp-
cAMPS (10 µM), again did not affect production of COX-
2 or iNOS 2 hrs after addition of isoproterenol, when
compared to cells pretreated in the absence of inhibitor
(Figure 6). In these experiments, levels of COX-2 gener-
ated by β-AR activation in the presence of H-89 (n = 3) or
Rp-cAMPS (n = 3) were increased 3.0 ± 0.4 and 2.5 ± 0.7
fold over basal, respectively. This level of COX-2
expression in response to isoproterenol was not signifi-
cantly different from cells pretreated in the absence of
inhibitor (1.9 ± 0.5 fold over basal; n = 5). Likewise, levels
β-AR stimulation activates the MAPK pathway after treatment with selective PKA inhibitors Figure 5
β-AR stimulation activates the MAPK pathway after treatment with selective PKA inhibitors. After a 30 min pre-
incubation with 100 nM of the PKA inhibitors H-89 (panel A) or 10 µM of Rp-cAMPS (panel B), UROtsa cells were stimulated 
with 100 nM isoproterenol for the indicated times and immunoblotted with anti-pERK or anti-ERK2. Peak levels of pERK were 
observed within 5 min after the addition of isoproterenol with no changes in the total cell lysate levels of ERK2. Semi-quanti-
tave analysis of the immunoblots revealed a time-dependent increase in ERK phosphorylation (panel C). Five minutes after 
treatment, isoproterenol significantly induced a 1.9 ± 0.4 and 2.6 ± 0.7 fold increase in pERK levels over basal after H-89 or Rp-
cAMPS pretreatment, respectively. These peak values are not significantly different than the fold increase over basal for pERK 
measured in the absence of PKA inhibitor (2.6 ± 0.9). Values are presented as the mean ± S.E. and the autoradiographs are rep-
resentative immunoblots of n = 3–4 independent UROtsa cell treatments.Cell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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of β-AR mediated iNOS production after H-89 (1.8 ± 0.3
fold over basal; n = 5) or Rp-cAMPS pretreatment (2.2 ±
0.6 fold over basal; n = 3) were not significantly different
from levels seen in the absence of PKA inhibitors (2.0 ±
0.7 fold over basal; n = 3). These results provide evidence
for selective production of inflammatory mediators in
UROtsa cells through activation of β-ARs that is inde-
pendent of PKA.
PKA-Dependent Phosphorylation of the Cyclic AMP-
Responsive Element Binding Protein
Since our results reveal no changes in the amount of ERK
phosphorylation or induction of COX-2 and iNOS after
pretreatment with selective concentrations of H-89 or Rp-
cAMPS, it was necessary to confirm that these PKA inhib-
itors were being used effectively in our system. Therefore,
we examined the isoproterenol mediated phosphoryla-
β-AR stimulated expression of pro-inflammatory mediators occurs through PKA-independent mechanisms Figure 6
β-AR stimulated expression of pro-inflammatory mediators occurs through PKA-independent mechanisms. 
After a 30 min pre-incubation with 100 nM of H-89 (panel A) or 10 µM of Rp-cAMPS (panel B), UROtsa cells were stimulated 
with 100 nM isoproterenol in serum-free DMEM for the indicated times and immunoblotted with anti-COX-2 or anti-iNOS 
antibody to determine β-AR mediated changes in protein expression. Peak UROtsa cell expression of the pro-inflammatory 
mediators COX-2 and iNOS was observed 2 hrs after addition of isoproterenol even after pre-incubation with selective PKA 
inhibitors (panels C and D). Levels of COX-2 generated in the presence of H-89 or Rp-cAMPS were significantly increased 3.0 
± 0.4 and 2.5 ± 0.7 fold over basal, respectively. However these isoproterenol induced levels of COX-2 were not significantly 
different from cells pretreated in the absence of inhibitor (1.9 ± 0.5 fold over basal). Likewise, levels (fold over basal) of iNOS 
production generated by isoproterenol after H-89 (1.8 ± 0.3) or Rp-cAMPS pretreatment (2.2 ± 0.6) were significantly greater 
than basal. However these responses were not significantly different from levels observed for isoproterenol induced iNOS 
production in the absence of PKA inhibitors (2.0 ± 0.7). Values are presented as the mean ± S.E. and the autoradiographs are 
representative immunoblots of n = 3–5 independent UROtsa cell treatments.Cell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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tion state of the cAMP responsive element binding protein
(CREB) in the absence and presence of selective concen-
trations of H-89 or Rp-cAMPS. CREB is a well character-
ized transcriptional factor, which is activated by cAMP-
dependent PKA phosphorylation of specific serine resi-
dues [16]. In our experiments, the isoproterenol induced
phosphorylation state of CREB was observed over a 2 hr
interval (Figure 7). In the absence of PKA inhibitors, iso-
proterenol increased the phosphorylation state of CREB
within 5 min returning to basal after 60 min (n = 3). This
time course for CREB phosphorylation is similar to what
has been described by others [17]. Pretreatment of
UROtsa cells with 100 nM H-89 or 10 µM Rp-cAMPS
significantly blocked the isoproterenol mediated CREB
phosphorylation (n = 3). These results confirm that selec-
tive concentrations of H-89 and Rp-cAMPS used for this
study can effectively block a cAMP-dependent PKA phos-
phorylation process. Furthermore, this finding supports
our previous observations that the selective production of
inflammatory mediators through induction of β-ARs is
unrelated to the cAMP-dependent activation of PKA.
Discussion
This study characterizes a novel role of β-AR signaling in
urothelial cells that leads to selective induction of protein
products associated with inflammatory responses. Our
results demonstrate that a previously described human
urothelial cell line expressing functional β-ARs increases
production of cAMP, phosphorylated ERK and height-
ened translation of COX-2 and iNOS in response to
agonist activation. β-AR stimulation classically precedes
cAMP accumulation, which regulates the activity of PKA
leading to phosphorylation of PKA-sensitive substrates.
However, phosphorylation of ERK and selective produc-
tion of inflammatory mediators in UROtsa cells occurs
independently of PKA activation, as similar results were
observed in the presence of two analogous inhibitors spe-
cific for this cAMP-dependent kinase. Effective use of
these compounds was confirmed by documenting the
inhibition of PKA dependent protein phosphorylation in
our same model system. Therefore, functional β-ARs
present on these human urothelial cells elicit pro-inflam-
matory responses by a PKA-independent mechanism.
Previous studies by others have demonstrated the link
between activation of MAPK pathways and the induction
of inflammatory mediators [14]. In these studies, receptor
regulated expression of COX-2 and iNOS was dependent
upon the intermediary phosphorylation of ERK. Moreo-
ver, β-AR activation, although classically linked to genera-
tion of cAMP, has been shown in other studies to
influence MAPK activation in a PKA-independent manner
[18]. These PKA-independent mechanisms associated
with β-AR mediated phosphorylation of ERK have been
shown to involve β-arrestin scaffolding complexes [18]. In
our studies we show that β-AR mediated ERK phosphor-
ylation in UROtsa cells is independent of active cAMP-
dependent PKA. Whether other scaffolding complexes
caused by β-AR stimulation in these cells are associated
with ERK phosphorylation is currently under investiga-
tion by our laboratory.
Despite the fact that a specific etiology has yet to be iden-
tified, inflammatory pain is a common mechanism asso-
ciated with the symptoms of IC [1]. With reference to our
human urothelial cell model, we demonstrate an induc-
tion of mediators associated with inflammatory pain and
bladder hyperexcitability in response to β-AR activation.
Clinical correlations have recognized an increased sympa-
thetic innervation as well as elevated catecholamine levels
in IC patients when compared to controls [9,10]. Our
studies suggest that chronic urothelial β-AR stimulation in
these patients may induce COX-2 and iNOS leading to the
increased progression of inflammatory pain and bladder
hyperexcitability associated with this disease. Induction of
COX-2 by bacterial lipopolysaccharide or endogenous
cytokines has been shown to elevate prostanoid levels that
PKA inhibitors H-89 and Rp-cAMPS block phosphorylation of  CREB Figure 7
PKA inhibitors H-89 and Rp-cAMPS block phosphor-
ylation of CREB. After a 30 min pre-incubation with 
serum-free DMEM alone or with 100 nM of H-89 or 10 µM 
of Rp-cAMPS, UROtsa cells were stimulated with 100 nM 
isoproterenol in serum-free DMEM for the indicated times 
and immunoblotted with an antibody specific to CREB phos-
phorylated at S129 and S133 (pCREB). Without inhibitor 
pretreatment, isoproterenol induced CREB phosphorylation 
within 5 min. Significant phosphorylation was still observed 
15 min. after drug addition with banding intensity patterns 
similar to basal after 60 min. Preincubation with H-89 or Rp-
cAMPS significantly decreased the phosphorylation of CREB 
at the 5 and 15 min time points in UROtsa cells, demonstrat-
ing the effectiveness of PKA inhibition for these compounds. 
As reported by the antibody suppliers, pCREB is identified as 
a band running at 43 kD. The second band seen on the auto-
radiographs represents a previously-reported alternative 
splice variant of CREB. Autoradiographs are representative 
immunoblots of n = 3 independent cell treatments.Cell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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are linked to the increased vasodilatation, vascular perme-
ability and hyperalgesic responses of inflammation [2]. In
other models, induction of iNOS by these same agonists
to generate nitric oxide contributes to the nociceptive
processing of inflammatory pain [19]. Therefore, we sug-
gest that chronic urothelial β-AR stimulation leading to
increased levels of prostaglandins and NO is one potential
mechanism of inflammatory pain in IC. Moreover, higher
levels of prostanoids and NO may also contribute to the
symptomatic increases in urinary frequency and urgency
diagnosed in patients with IC [4,8].
Support of this hypothesis has been reported using a
mouse model of bladder inflammation in which genes
encoding for iNOS and the β2-AR subtype were upregu-
lated when compared to control [11]. Interestingly, a
significant increase in genomic expression of the β2-AR
subtype was only observed in a chronic and not an acute
bladder inflammation model. Conversely, other investi-
gators have shown using transient application of β-AR
agonists that an increase in cAMP is sufficient to generate
maintenance levels of NO in primary rat urothelial cells
[20]. However, our studies using a human urothelial cell
model, demonstrates that cAMP-dependent PKA activa-
tion is not necessary to induce inflammatory mechanisms
for generating NO. Moreover, generation of homeostatic
levels of NO in the rat model was sensitive to Ca2+ indicat-
ing that the responsible enzyme was eNOS, although tran-
scriptional message (mRNA) for iNOS was well
documented in this same report [20]. This suggests that
chronic β-AR stimulation may induce expression of iNOS,
which would generate higher levels of NO contributing to
the production of inflammatory pain and increased mic-
turition associated with IC.
In our human urothelial cell model we document a β-AR
stimulated, PKA-independent signaling pathway that
simultaneously increases the expression of two mediators
of inflammation, COX-2 and iNOS. In addition, the
pathophysiology linked to increased prostaglandin and
NO production correlate well with the clinical manifesta-
tions associated with chronic inflammatory diseases like
IC. Consequently, we believe that UROtsa cells serve as a
readily accessible model for studying the β-AR-effector
system associated with inflammation in IC. Nonsteroidal
anti-inflammatory drugs (NSAIDs), which block the
synthesis of prostaglandins by inhibiting COX, are com-
monly prescribed to relieve discomforts associated with
IC. Moreover, NSIADs have been shown to decrease the
amount of NO in vivo indicating the importance of COX-
2 activity in regulating NO production during
inflammation [21]. Furthermore, combined pharmaco-
logical inhibition of COX-2 and iNOS in a rat model of
tonic pain, produces a synergistic antinociceptive effect
[22]. This data suggests a common mechanism of action
between these two drug classes, however, the associations
between COX-2 and iNOS effector systems are currently
unknown. Therefore, UROtsa cells represent a unique cell
model whereby signal-transduction pathways common to
the induction of both COX-2 and iNOS can be investi-
gated. These studies not only may reveal novel targets of
inflammatory pain that could be exploited therapeuti-
cally, but would increase our understanding of the
etiology for general bladder inflammation and hyperexcit-
ability in IC.
Conclusion
Stimulation of β-ARs expressed on cultured human
urothelial cells leads to ERK phosphorylation and produc-
tion of the pro-inflammatory enzymes. While cAMP levels
rise in these cells after β-AR activation, production of
COX-2 and iNOS are not dependent upon an increased
cAMP regulated PKA activity. Continual initiation of AR
function documented for patients diagnosed with IC
would likely stimulate urothelial cell inflammatory
responses thereby contributing to the etiology of this
disease. Our results suggest that by focusing on common
urothelial β-AR mediated inflammatory signaling path-
ways, reasonable pathophysiological mechanisms and
potential therapeutic strategies could be developed for
chronic inflammatory diseases like IC.
Methods
Cell Culture
The immortalized human urothelial (UROtsa) cell line
was a gift from Donald Sens (University of North Dakota)
and was propagated as previously reported [12]. Briefly,
undifferentiated UROtsa cells were grown to confluence
in serum-containing Dulbecco's Modified Eagle's
Medium (DMEM) under standard cell culture conditions.
Confluent UROtsa cells were washed in serum-free
DMEM and pre-incubated with or without inhibitors pro-
tein kinase A (PKA) inhibitors 1 hr before addition of the
selective β-AR agonist, isoproterenol. The PKA inhibitors
H-89 (Sigma, St. Louis, MO) was used at a final concen-
tration of 100 nM, while Rp-cAMPS (BioLog, Bremen,
Germany) was used at 10 µM. Unless noted otherwise,
isoproterenol (Sigma, St. Louis, MO) was added to cells at
a final concentration of 100 nM. As a nonspecific initiator
of inflammation control, cells were incubated with 300
nM lipopolysaccharide (CalBioChem, La Jolla, CA).
Membrane Preparation
A crude cell membrane preparation was prepared as previ-
ously described [23]. Briefly, UROtsa membranes were
prepared by transferring suspended cells to a 50 mL
conical tube and twice washing by centrifugation at 1000
× g using cold Hank's balance salt solution (HBSS). The
intact cell pellet was resuspended in 10 mL of 0.25 M
sucrose containing 10 µg/mL bacitracin, 10 µg/mL benza-Cell Communication and Signaling 2005, 3:10 http://www.biosignaling.com/content/3/1/10
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midine, 10 µg/mL leupeptin, and 20 µg/mL phenylmeth-
ysulfonylfluoride. The cells were disrupted by freezing
followed by Dounce homogenization of the thawed sus-
pension using 20 strokes from a loose fitting (B) pestle.
This mixture was then centrifuged at 1260 × g for 5 min at
4°C. Buffer A (20 mM HEPES, pH 7.5, 1.4 mM EGTA,
12.5 mM MgCl2) was added to the supernatant and cen-
trifuged again at 30,000 × g  for 15 min at 4°C. The
resultant pellet was kept, resuspended in buffer A then
centrifuged once more at 30,000 × g for 15 min at 4°C.
The final crude membrane pellet was resuspended in
buffer A containing 10% glycerol and stored in aliquots at
-70°C until used for radioligand binding. Protein concen-
trations were measured using the method of Bradford
[24].
Radioligand Binding
The radioligand binding protocol used for this study was
performed as previously described [13]. Briefly, the den-
sity of expressed β-ARs on UROtsa cells was determined
by saturation binding experiments using the nonselective
β-AR antagonist 125I-CYP as the radiolabel (NEN Life
Sciences, Boston, MA). Crude UROtsa cell membranes
were allowed to equilibrate at 37°C with increasing con-
centrations of 125I-CYP (5–600 pM) in a 0.25 mL total vol-
ume of buffer A using 10-5 M propranolol to determine
non-specific binding. Binding was stopped by filtering the
membranes though Whatman GF/C glass fiber filters, fol-
lowed by 5 – 5 mL washes with cold buffer A to remove
any unbound drug. Amounts of total and non-specific
radiolabel bound to cell membranes were calculated from
radioactive counts remaining on the glass fiber filters.
From the plotted saturation hyperbola, β-AR density
(Bmax) and the equilibrium dissociation constant (Kd) of
125I-CYP for specific UROtsa cell binding sites were calcu-
lated using iterative non-linear regression analysis [25].
cAMP Assay
Confluent UROtsa cells used for the quantification of
cAMP were treated in serum-free DMEM containing 1 mM
1-methyl-3-isobutylxanthine (IBMX) to inhibit phos-
phodiesterase. After 30 min of isoproterenol treatment,
cells were lysed using 0.1 M HCl and collected for deter-
mination of cAMP production according to the Biotrak
Assay System protocol (Amersham, Buckinghamshire,
UK). Briefly, 3H-cAMP added to cell lysates was used to
compete with endogenous cAMP for binding to a specific
cAMP-binding protein. 3H-cAMP levels were then counted
by liquid scintillation and related to endogenously gener-
ated cAMP by comparison with known standards. The
concentration of isoproterenol that caused a half-maxi-
mal generation of cAMP (EC50) was calculated from non-
linear regression analysis using Prism 4 (Graphpad Soft-
ware, San Diego, CA).
Western Hybridization
After an appropriate period of time, treated cells were
lysed using a modified RIPA buffer (150 mM NaCl, 10
mM Tris, pH 7.2, 0.1% sodium dodecylsulphate, 1.0%
Triton X-100, 1.0% sodium deoxycholate, 5 mM EDTA,
1.0% protease inhibitor cocktail; Sigma, St. Louis, MO).
Total cell lysate protein concentrations were estimated
using Bradford protein assay reagent (Bio-Rad, Hercules,
CA) before lysates were resolved by SDS-PAGE and trans-
ferred to nitrocellulose membranes. Protein expression
was measured by 4°C overnight immunoblotting with
diluted antibodies: extracellular signal-regulated kinase 2
(mouse monoclonal ERK2, 1:1000; Santa Cruz Biotech-
nology, Santa Cruz, CA), phosphorylated ERK1/2 (mouse
monoclonal pERK, 1:500; Santa Cruz Biotechnology),
COX-2 (goat polyclonal, 1:500; Santa Cruz Biotechnol-
ogy) iNOS (rabbit polyclonal, 1:500; Santa Cruz Biotech-
nology) and phosphorylated CREB (rabbit polyclonal,
1:1000; AbCam, Cambridge, MA). After washing, mem-
branes were incubated at 25°C for 90 min with diluted
horseradish peroxidase-linked secondary antibody
(1:1000–5000). Bound antibody was visualized by the
Supersignal West Pico chemiluminescent system (Pierce,
Rockford, IL) and exposed to radiographic film. Devel-
oped films were subsequently photographed and protein
band intensity was estimated by semi-quantitative densit-
ometric methods using LabWorks v.4.5 (UVP, Upland,
CA). Protein levels are presented as the mean fold increase
in pixel intensity over control, plus or minus the standard
error for n experiments. Differences between control and
drug treated groups was determined using a paired one-
tailed Student's t test with a p < .05 level of probability
accepted as significant. Equal protein loading was con-
firmed by Ponceau-S staining of nitrocellulose
membranes.
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